Yonago acta medica, Год журнала: 2025, Номер 68(2), С. 91 - 105
Опубликована: Янв. 1, 2025
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a significant global health concern, affecting approximately 30% of the population. In Japan, its prevalence is also rising rapidly and expected to reach 50% by 2040. This situation can be described "MASLD pandemic", emphasizing urgent need for effective therapeutic interventions. Peroxisome proliferator-activated receptors (PPARs) are nuclear that play essential roles in lipid metabolism, inflammation regulation, fibrosis modulation. Among them, PPARα key regulator homeostasis, primarily expressed other metabolically active tissues. Its activation promotes fatty acid oxidation improves profiles, making it crucial target metabolic disorders. novel selective modulator (SPPARMα) was developed lipid-lowering agent treating dyslipidemia. Over time, increasing clinical evidence suggested SPPARMα beneficial effects on MASLD patients' function. review aims summarize potential examining functional mechanisms PPARα, preclinical studies animal models, accumulating from patients. Furthermore, we provide an overview ongoing trials investigating treatment.
Язык: Английский